Leah Kuntz

What is new in research on major depressive disorder?

Government funding cuts to mental health and addiction programs create chaos, prompting swift restoration amid widespread concern from advocacy groups. Read the statement from the AFSP here.

BioXcel Therapeutics submits an sNDA to the FDA for Igalmi to treat agitation in bipolar disorder and schizophrenia at home.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

Axsome Therapeutics begins a pivotal trial for AXS-14, aiming to improve fibromyalgia management and address significant patient needs.

New data reveals valbenazine (Ingrezza) shows significantly higher VMAT2 target occupancy than deutetrabenazine (Austedo XR).

Explore groundbreaking insights from the 2025 Southern Florida Psychiatry Conference, covering VNS for depression, stuttering management, and postpartum care.

Scienture's Rezenopy, the highest-dose naloxone nasal spray approved by the FDA, gains patent protection.

FDA removes suicidal ideation warnings from GLP-1 RA medications, highlighting their potential benefits in weight loss and mental health treatment.

Cassava Sciences shares insights from phase 3 trials of simufilam for Alzheimer disease, revealing potential treatment differences despite unmet primary endpoints.

FDA approves ProlivRx, a groundbreaking at-home therapy for major depressive disorder, offering new hope for patients unresponsive to traditional treatments.

Lipocine's LPCN 1154 shows promise in treating postpartum depression, with a strong safety profile and potential for rapid relief in outpatient settings.

Reviva Pharmaceuticals reveals promising clinical trial data on brilaroxazine, highlighting its potential to treat negative symptoms in schizophrenia.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

Explore the vital role of consultation liaison psychiatry in enhancing patient care and emotional well-being in complex medical conditions in our January 2026 theme!

MapLight Therapeutics advances treatment for Alzheimer disease psychosis with FDA Fast Track designation for ML-007C-MA, targeting hallucinations and delusions.

Biohaven's BHV-7000 fails to reduce depressive symptoms in a phase 2 proof-of-concept study.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

Check out the pipeline updates from December!

Need CME credit? We've got you covered.

Discover new research on schizophrenia treatments, including digital therapeutics and valbenazine, showcasing significant improvements in patient outcomes.

AFSP's new CAPS program empowers health care professionals with essential skills to identify and support patients at risk for suicide effectively.

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.

What were the top psychiatric hits of 2025?

Incannex Healthcare's PSX-001 shows promise in treating generalized anxiety disorder, offering innovative, effective solutions beyond traditional therapies.

A critical shortage of IV lorazepam disrupts psychiatric care, particularly for patients with catatonia, highlighting broader pharmaceutical supply chain issues.

Bristol Myers Squibb expands patient enrollment in the ADEPT-2 study, exploring Cobenfy's potential for treating Alzheimer disease-related psychosis.